Slaoui is noted for his work with Operation Warp Speed, the COVID-19 vaccine project launched by the Trump administration, where he was scientific head until he stepped down in January.

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.